This inventor holds 2 USPTO granted patents. Top assignee: Synthelabo. Active years: 1987-1994.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Fontenay Aux Roses, FR (1987)
- Sceaux, FR (1994)
Company Filing History:
Years Active: 1987-1994
Title: The Innovations of Jean Pierre Merly
Introduction
Jean Pierre Merly is a notable inventor based in Sceaux, France. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative patents. With a total of 2 patents, Merly's work focuses on compounds that have potential therapeutic applications.
Latest Patents
Merly's latest patents include a compound known as 2-amino-N- which is a pyrimidine-4-carboxamide derivative. This compound is characterized by the general formula (I), where n is 0 or 1, and m is 0 or 1. Another significant patent involves 2-(4,5-Dihydro-1H-imidazol-2-yl)-2,3-dihydroindole derivatives. These derivatives are defined by a formula (I) in which X can be a hydrogen or halogen atom, an alkoxy radical, an alkyl radical, or an allyloxy radical. R denotes various types of radicals, including linear or branched alkyl, cycloalkylalkyl, alkenyl, and arylalkyl radicals, which may have substituents such as halogen atoms and methyl, methoxy, and methylenedioxy radicals. These compounds exhibit an .alpha..sub.2 -receptor antagonist effect, showcasing their potential in pharmaceutical applications.
Career Highlights
Jean Pierre Merly is associated with Synthelabo, a company known for its focus on pharmaceutical innovations. His work has contributed to advancements in drug development and therapeutic solutions.
Collaborations
Merly has collaborated with notable coworkers, including Benoit Marabout and Jacques Menin. Their combined expertise has likely enhanced the quality and impact of their research and innovations.
Conclusion
Jean Pierre Merly's contributions to the field of pharmaceuticals through his patents demonstrate his innovative spirit and dedication to advancing medical science. His work continues to influence the development of new therapeutic compounds.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile